SCHEMBL17257481

SCHEMBL17257481

N#CC1CCCC(C=NOCc2ccccc2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
GAA P10253 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
G6PC1 P35575 1/20 0.35
LTA4H P09960 1/20 0.34
CTSL P07711 2/20 0.33
CTSB P07858 2/20 0.33
CTSK P43235 2/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
GLA P06280 1/20 0.32
DPP4 P27487 2/20 0.32
DPP7 Q9UHL4 1/20 0.32
PREP P48147 2/20 0.31
USP8 P40818 2/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257480 1.00 NPC1 (0.39) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257053 0.96 G6PC1 (0.40) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257050 0.96 G6PC1 (0.40) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257540 0.90 NPC1 (0.39) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257541 0.90 NPC1 (0.39) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257222 0.87 G6PC1 (0.41) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257223 0.87 G6PC1 (0.41) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL4801137 0.77 G6PC1 (0.42) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL2475785 0.77 G6PC1 (0.42) NPC1RAB9AGAASMN1; SMN2G6PC1
SCHEMBL17257096 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
EP-3143055-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP Bridgestone Corporation (JP) 2017-03-22 EP claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
WO-2015175280-A2 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 WO claimed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB NPC1 4775/4885RAB9A 4587/4885GAA 2104/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB NPC1 4775/4885RAB9A 4587/4885GAA 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.